JA
VRTX icon

John Armitage’s Vertex Pharmaceuticals VRTX Stock Holding History

John Armitage’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-124,045
Closed -$57.7M – 37
2024
Q3 		$57.7M Buy
+124,045
New +$59.6M 0.58% 26

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

John Armitage's VRTX Position: Q4 2024 in Review

John Armitage sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 124,045 shares — an estimated $57.7M sold.

John Armitage first reported a position in VRTX in Q3 2024 and held it in 1 quarter. The position peaked at $57.7M in Q3 2024. 1,560 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • John Armitage reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • John Armitage sold 124,045 Vertex Pharmaceuticals shares in Q4 2024, an estimated $57.7M.
  • John Armitage first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • John Armitage's Vertex Pharmaceuticals position peaked at $57.7M in Q3 2024.
  • 1,560 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Egerton Capital (UK)'s 13F filing for Q4 2024, filed 10 Feb 2025.